Envelope and pre-membrane protein structural amino acid mutations mediate diminished avian growth and virulence of a Mexican West Nile virus isolate

Stanley A. Langevin,1 Richard A. Bowen,2 Wanichaya N. Ramey,1 Todd A. Sanders,3† Payal D. Maharaj,1 Ying Fang,1 Jennine Cornelius,1 Christopher M. Barker,1 William K. Reisen,1 David W. C. Beasley,4 Alan D. T. Barrett,4 Richard M. Kinney,5 Claire Y.-H. Huang5 and Aaron C. Brault1,5

1Center for Vectorborne Diseases and Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
2Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
3Colorado Division of Wildlife, Fort Collins, CO 80526, USA
4Departments of Pathology and Microbiology and Immunology, Center for Emerging Infectious Diseases and Biodefense, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA
5Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA

The hallmark attribute of North American West Nile virus (WNV) strains has been high pathogenicity in certain bird species. Surprisingly, this avian virulent WNV phenotype has not been observed during its geographical expansion into the Caribbean, Central America and South America. One WNV variant (TM171-03-pp1) isolated in Mexico has demonstrated an attenuated phenotype in two widely distributed North American bird species, American crows (AMCRs) and house sparrows (HOSPs). In order to identify genetic determinants associated with attenuated avian replication of the TM171-03-pp1 variant, chimeric viruses between the NY99 and Mexican strains were generated, and their replicative capacity was assessed in cell culture and in AMCR, HOSP and house finch avian hosts. The results demonstrated that mutations in both the pre-membrane (prM-I141T) and envelope (E-S156P) genes mediated the attenuation phenotype of the WNV TM171-03-pp1 variant in a chicken macrophage cell line and in all three avian species assayed. Inclusion of the prM-I141T and E-S156P TM171-03-pp1 mutations in the NY99 backbone was necessary to achieve the avian attenuation level of the Mexican virus. Furthermore, reciprocal incorporation of both prM-T141I and E-P156S substitutions into the Mexican virus genome was necessary to generate a virus that exhibited avian virulence equivalent to the NY99 virus. These structural changes may indicate the presence of new evolutionary pressures exerted on WNV populations circulating in Latin America or may signify a genetic bottleneck that has constrained their epiornitic potential in alternative geographical locations.

INTRODUCTION

Since West Nile virus (WNV) was first identified in New York City in 1999, evidence for viral transmission has been documented throughout the western hemisphere, indicating the potential establishment of endemic transmission cycles as far south as Argentina (Adrián Díaz et al., 2008). Surveillance studies conducted in Mexico (Estrada-Franco et al., 2003; Farfán-Ale et al., 2004, 2006), Central America (Morales-Betoule et al., 2006), the Caribbean (Barrera et al., 2008; Dupuis et al., 2003; Komar et al., 2005) and South America (Bosch et al., 2007; Mattar et al., 2005) have
provided serological evidence of transmission of WNV but have generated few WNV isolates, possibly indicating limited or highly focal transmission of the virus within Latin America (Bosch et al., 2007; Dupuis et al., 2005; Komar & Clark, 2006). Avian virulence, a common feature associated with North American WNV transmission in the USA and Canada, has not been reported in Latin America or the Caribbean, and plaque variants of a WNV isolate from Tabasco State, Mexico, in 2003 have demonstrated reduced avian viraemia production and virulence in American crows (AMCRs) and house sparrows (HOSPs) (Brault et al., 2011). The implementation of WNV deadbird surveillance programmes in North America has enhanced surveillance efforts (Eidson, 2001), serving to foreshadow WNV epizootics, and has provided an invaluable source of viral isolates for genotypic and phenotypic characterization (Guptill et al., 2003; Komar, 2001; Mostashari et al., 2003). The paucity of avian mortality in Latin America has undoubtedly contributed to the dearth of knowledge of enzootic transmission mechanisms in Latin America.

The basis for the apparent lack of avian mortality in Latin America has not been demonstrated conclusively; however, several plausible explanations to account for this observation include: (i) pre-existing immunity in avian populations to closely related flaviviruses, reducing the pathogenesis of secondary WNV infections (Farfán-Ale et al., 2009); (ii) natural resistance of avian species in Latin America to lethal WNV infection (Reed et al., 2009); (iii) dampened transmission associated with increased avian biodiversity in more tropical latitudes (Ezenwa et al., 2006; Johnson & Thielges, 2010; Swaddle & Calos, 2008); (iv) reduced surveillance efforts; (v) reduction in the avian virulence potential of a founding strain; and (vi) selection for a genotype with reduced avian virulence potential. The isolation of a murine and avian attenuated WNV variant (TM171-03-pp1) from a raven in Tabasco State, Mexico (Beasley et al., 2004), with reduced avian pathogenic properties (Brault et al., 2011) indicates that strains with altered pathogenic characteristics have circulated in Mexico. Similarly attenuated strains have also been identified in Texas (Brault et al., 2011; Davis et al., 2004).

Isolates of WNV from Northern Mexico (Davis et al., 2005; Elizondo-Quirorga et al., 2005) in close proximity to the US border as well as in Puerto Rico (Barrera et al., 2008) have been demonstrated to be most synonymous with the North American genotype (WN02), which, subsequent to 2002, has largely displaced the East Coast North American founding genotype (NY99). The lack of sequence data available on WNV isolates collected in the Caribbean and much of Latin America has precluded the specific identification of genotypic changes associated with transmission in these ecosystems. The Mexican TM171-03 plaque variant from the brain of a raven consists of mixed-plaque phenotypes: a small-plaque variant (TM171-03-pp1; GenBank no. JN051152) lacking a functional envelope protein (E) glycosylation motif (NYP, at aa 154–156) and a large-plaque variant (TM171-03-pp5; GenBank no. JN051153) exhibiting a functional NYS glycosylation motif (Beasley et al., 2004). In a murine model, E protein N-glycosylation of North American WNV strains has been positively correlated with neuroinvasive capacity and disease severity (Beasley et al., 2005; Shirato et al., 2004). The murine virulence phenotype did not appear to be attenuated by the presence of additional amino acid substitutions [I141T in the pre-membrane protein (prM), I245V in non-structural protein NS4B and T898I in non-structural protein NS5] or the nucleotide substitutions in the 5′- and 3′UTRs of the genome of the glycosylated TM171-03-pp5 variant (Beasley et al., 2004). Avian studies utilizing the non-glycosylated WNV TM171-03-pp1 variant demonstrated a decreased peripheral replication in AMCRs and HOSPs, with higher survival rates observed in the AMCR model when compared with avian virulent NY99 and TWN301 isolates (Brault et al., 2011). The glycosylation-competent plaque-purified variant WNV TM171-03-pp5 also demonstrated an attenuated phenotype in AMCRs and HOSPs compared with the NY99 isolate, indicating the contribution of other amino acid residues or non-coding nucleotide changes to reduced replication of the WNV TM171-03 plaque variants in avian hosts.

In order to assess directly the role of N-linked glycosylation and accessory mutations in the attenuation of avian replication of the TM171-03-pp1 isolate, non-synonymous genetic differences between the WNV TM171-03-pp1 variant and NY99 virus were introduced into a virulent WNV NY99 infectious cDNA clone (WN/IC-P991) (Kinney et al., 2006) singly or in combination (Table 1). The replication phenotypes of viruses generated from these recombinant constructs were tested in vitro in HD11 avian macrophages and in vivo in AMCRs for a direct assessment of the relative attenuating role of TM171-03-pp1 mutations, singly or in combination. To assess whether the attenuating effects of substitutions were avian species specific, viraemias were also assessed in two additional passerine bird species, HOSPs and house finches (HOFIs).

**RESULTS**

**Generation and phenotypic characterization of WNV NY99/MX03 mutants**

Mutagenesis was performed on both 5′ and 3′ plasmid cassettes, and differential ligation of mutated and parental plasmids was used for the successful generation of 14 recombinant viruses from WNV NY99 and the Mexican TWN171-03 clone-derived virus containing the same prM-I141T and E-156P residues (WN-MX03/IC) (Table 1). Infectious virus was rescued for all recombinant constructs and all viruses grew to at least 8 log10 p.f.u. ml⁻¹ by 96 h post-infection (p.i.) (the growth profile of a subset of viruses is shown in Fig. 1). Initial plaque morphologies were visualized in Vero cells using crystal violet to stain the
cell monolayer, and viral plaque diameters were measured. At 72 h p.i., the parental WNV TM171-03-pp1 plaque variant exhibited a mean diameter of 2.1 ± 0.6 mm that was indistinguishable from the WN-MX03/IC virus (1.9 ± 0.5 mm) and WN-MX03/IC-prM.E virus containing both the prM-141T and E-156P mutations (1.9 ± 0.3 mm) (Table 2). The WN/IC-E mutant with the E-S156P substitution exhibited an intermediate plaque size phenotype of 3.2 ± 0.3 mm, distinguishable from both the WN/IC-P991 and WN-MX03/IC viruses (P < 0.05). In contrast, the WN/IC-P991 wild-type virus and mutant WN-MX03/IC-prM.E virus (containing the prM-141I and E-156S mutations in the TM171-03-pp1 backbone) exhibited an indistinguishable large-plaque phenotype in Vero cells (4.5 ± 0.4 and 4.4 ± 0.3 mm, respectively), implicating a role of both the prM and E substitutions in the small-plaque phenotype of the TM171-03-pp1 plaque variant. Small reductions in growth in Vero cells were also identified for WN/IC mutants containing either the prM-141T (WN/IC-prM.) or E-S156P (WN/IC-E) substitution; however, the complete 11-fold reduction in titre identified with the TM171-03-pp1 variant was achieved only by incorporation of both structural mutations (WN/IC-prM.E; Fig. 1).

Avian monocyte growth phenotype characterization

As previous studies have implicated the importance of monocyte-derived cells as sites of initial virus replication and differential induction of innate immune responses (Garcia-Tapia et al., 2007; Silva et al., 2007; Steele et al., 2000; Wünschmann et al., 2004), all WN/IC mutants generated (Table 1) were assessed for growth in an HD11

Table 1. Genetic differences between parental (WN/IC-P991 and WN-MX03) and point-mutant viruses generated

Nucleotide numbers correspond to WNV NY99 (strain 382-99) genomic positions. Nucleotide positions are presented for 5'- and 3'UTR mutations and amino acid positions within respective genes are presented for amino acid changes. Amino acid substitutions are presented in upper case and nucleotide substitutions in lower case. Dashes represent the same nucleotide or amino acid identity compared with the WN/IC-P991 sequence.

<table>
<thead>
<tr>
<th>Parental/ mutant recombinant virus</th>
<th>5'UTR (nt 50)</th>
<th>5'UTR (nt 71)</th>
<th>prM (aa 141)</th>
<th>E (aa 156)</th>
<th>NS4B (aa 245)</th>
<th>NS5 (aa 898)</th>
<th>3'UTR (nt 10828)</th>
<th>3'UTR (nt 10989)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WN/IC-P991 (NY99)*</td>
<td>a</td>
<td>a</td>
<td>I</td>
<td>S</td>
<td>I</td>
<td>T</td>
<td>t</td>
<td>g</td>
</tr>
<tr>
<td>WN/IC-5'</td>
<td>g</td>
<td>g</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-prM</td>
<td>–</td>
<td>–</td>
<td>T</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-E</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>P</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-5’.prM.E</td>
<td>g</td>
<td>g</td>
<td>T</td>
<td>P</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-5’.E</td>
<td>g</td>
<td>g</td>
<td>–</td>
<td>P</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-prM.E</td>
<td>–</td>
<td>–</td>
<td>T</td>
<td>P</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-NS4B</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>V</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-E.NS4B</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>P</td>
<td>V</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-NS4B.NS5</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>V</td>
<td>I</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-3’</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>g</td>
<td>a</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>WN/IC-E.3’</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>P</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>g</td>
</tr>
<tr>
<td>WN/IC-5’.E.3’</td>
<td>g</td>
<td>g</td>
<td>–</td>
<td>P</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>g</td>
</tr>
<tr>
<td>WN-MX03/IC-prM.E</td>
<td>g</td>
<td>g</td>
<td>–</td>
<td>–</td>
<td>V</td>
<td>I</td>
<td>g</td>
<td>a</td>
</tr>
<tr>
<td>WN-MX03/IC</td>
<td>g</td>
<td>g</td>
<td>T</td>
<td>P</td>
<td>V</td>
<td>I</td>
<td>g</td>
<td>a</td>
</tr>
<tr>
<td>TM171-03-pp1†</td>
<td>g</td>
<td>g</td>
<td>T</td>
<td>P</td>
<td>V</td>
<td>I</td>
<td>g</td>
<td>a</td>
</tr>
</tbody>
</table>

*GenBank accession no. AF196835 (Lanciotti et al., 1999). These substitutions represent two additional genetic differences between the WN/IC-P991 and WN-MX03 strains presented within this table.

†Nucleotide and amino acid differences between the parental NY99 WNV (strain 382-99; synonymous with the exception of the abovementioned differences with WN/IC-P991) and the TM171-03-pp1 consensus sequence.
WN/IC backbone also failed to exhibit titres distinguishably lower than the wild-type WN/IC virus \((P>0.1;\) Fig. 2b). Introduction of the prM-141T mutation into the WN/IC genome (WN/IC-prM) significantly lowered \((P<0.001)\) the mean peak virus titre by 40-fold when compared with the WN/IC-P991 virus at 48 h p.i. (Fig. 2c). When both structural TM171-03-pp1 mutations (prM-141T and E-156P) were introduced into the WN/IC backbone in concert (WN/IC-prM,E), the mean peak virus titre was observed to be 450-fold lower than the WN/IC-P991 wild-type virus at 48 h p.i. \((P<0.001)\) (Fig. 2c). However, WN-MX03/IC, the Mexican TWN171-03 clone-derived virus containing the same prM-141T and E-156P residues, exhibited only a 56-fold lower mean peak titre compared with the WN/IC-P991 virus \((P<0.01)\) at 48 h p.i. (Fig. 2c), indicating a potential modulating effect afforded by alternative non-structural genetic changes in the TM171-03-pp1 backbone. The WN/IC-5',prM,E mutant demonstrated a peak viraemia indistinguishable from that of the WN-MX03/IC virus (Fig. 2c), indicating that a modulating effect was imparted by the two 5'UTR mutations in HD11 cells. Inclusion of the prM-141I and E-156S mutations in the WN-MX03/IC backbone resulted in a virus (WN-MX03/IC-prM,E) that was indistinguishable from the WN/IC-P991 in HD11 cells (Fig. 2b), supporting the dominant attenuating role of the combined prM and E mutations for retarded growth of the MX03 virus in HD11 cells.

### TM171-03-pp1 genetic determinants of attenuated avian replication

The viraemia in AMCRs following inoculation with virus derived from the WN-MX03/IC infectious cDNA was indistinguishable from that observed from the WNV TM171-03-pp1 variant (Fig. 3a), indicating the utility of this clone as a surrogate backbone for the incorporation of NY99-restoring avian virulence mutations. The mean peak viral load for AMCRs inoculated with the WN/IC-E virus was observed at 5 days p.i. compared with 4 days p.i. for the parental WN/IC-derived virus and was 1000-fold lower \((P<0.006)\) (Fig. 3b). This attenuated phenotype was observed following inoculation of AMCRs with all WNV NY99/MX03 mutants containing the E-S156P substitution (Fig. 3b and Supplementary Fig. S1, available in JGV Online). Inclusion of the NS4B and UTR genetic elements in various combinations with the E mutation failed to significantly modulate AMCR viraemia compared with the WN/IC-E virus (Supplementary Fig. S1). Both the wild-type WN/IC-P991 and WN/IC-prM mutant manifested mean peak viral titres at 4 days p.i., with the WN/IC-prM virus producing a threefold lower viraemia at that time point \((P>0.4;\) Fig. 3a). Peak titres observed for infection with the WN/IC-prM (Fig. 3a) and WN/IC-E (Fig. 3b) viruses were significantly different \((P<0.05)\). Mortality appeared to correlate well with the viraemia profiles observed in AMCRs (Fig. 4). Inoculation of the TM171-03-pp1 virus resulted in only 50% mortality, and the clone-derived WN-MX03/IC virus \((n=3;\) not shown in Fig. 4) elicited no mortality, whereas the WN/IC-P991 virus

---

**Table 2.** Mean plaque diameter of parental and NY99/MX03 WNV chimeric viruses at 72 h p.i.

<table>
<thead>
<tr>
<th>Virus</th>
<th>Plaque diameter (mm ± sd)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WN/IC-P991</td>
<td>4.5 ± 0.4</td>
</tr>
<tr>
<td>WN-MX03/IC</td>
<td>1.9 ± 0.5</td>
</tr>
<tr>
<td>TM171-03-pp1</td>
<td>2.1 ± 0.6</td>
</tr>
<tr>
<td>WN/IC-5',E,3'</td>
<td>3.3 ± 0.3</td>
</tr>
<tr>
<td>WN/IC-E</td>
<td>3.2 ± 0.3</td>
</tr>
<tr>
<td>WN/IC-prM,E</td>
<td>1.9 ± 0.3</td>
</tr>
<tr>
<td>WN-MX03/IC-prM,E</td>
<td>4.4 ± 0.3</td>
</tr>
</tbody>
</table>

---

**Fig. 1.** Mean viral titre ± SD of triplicate cultures of parental and NY99/MX03 point-mutant viruses in Vero cells inoculated at an m.o.i of 0.01, with a detection limit of 50 p.f.u. ml⁻¹.
yielded 100% mortality (n=8) within 6 days (Brault et al., 2011). A lower-than-expected mortality for the WN-MX03/IC virus compared with the parental TM171-03-pp1 virus was attributed to the small sample size, as viraemias generated by these two viruses were not distinguishable in AMCRs or HOSPs/HOFIs (Figs 4 and 5). Incorporation of the MX03 prM mutation into the WN/IC virus (WN/IC-prM) had a minimal effect on virulence, with only a single survivor being observed out of the six inoculated AMCRs (Fig. 4). Two of eight (25%) AMCRs inoculated with the recombinant WNV containing the MX03 E mutation (WN/IC-E) survived. The recombinant virus containing both the prM and E MX03 mutations (WN/IC-prM.E) demonstrated a mortality rate of 50% (n=6), identical to that of the parental TM171-03-pp1 strain (Fig. 4).

The attenuating growth capacity of the WNV TM171-03-pp1 structural mutations (prM-141T and E-156P) was also assessed in HOSPs, a common avian species that has been implicated previously as an important reservoir host for WNV (Reisen et al., 2005). Unlike the viraemia data generated for AMCRs, significant variability in the mean titres observed in HOSPs within viral infection groups confounded statistical analyses. This variability resulted from the failure of some birds within the groups to generate viraemia, despite seroconversion at 21 days p.i. As such, the limit of detection titre [1.7 log10 p.f.u. (ml serum)] was used for calculation of means. The WN/IC-prM and WN/IC-E viruses had one HOSP each and the WN/IC-prM.E infection group had two HOSPs that were seropositive, yet failed to generate detectable viraemias. The E-156P mutation reduced the magnitude of viraemia compared with the WN/IC-P991 virus in HOSPs by 91-fold at 3 days p.i. (Fig. 5a); however, the large variability in titres at this point for the prM mutant [range 1.7–6.4 log10 p.f.u. (ml serum)] obscured any inference of statistical significance (P>0.8) between the prM and E mutants. However, peak viraemias in HOSPs were identified at 3 days p.i. following infection with the WN/IC-prM mutant virus, with this mutant exhibiting a mean peak viral load 334-fold lower than the WN/IC-P991 virus (P=0.4) at this time point (Fig. 5a). When comparing the two TM171-03-pp1 structural mutations in the HOSP model, the WN/IC-prM mutant virus produced only an approximately fourfold lower mean peak viraemia than WN/IC-E (P>0.5) (Fig. 5a). Inclusion of both WNV TM171-03-pp1 structural mutations (WN/IC-prM.E) drastically reduced the mean peak viraemia by 57 000-fold when
compared with the WN/IC-P991 virus ($P<0.001$) (Fig. 5b). Reciprocally, incorporation of the prM-141I and E-156S mutations into the TM171-03-pp1 backbone (WN-MX03/IC-prM.E) restored the high-viraemia phenotype in HOSPs (Fig. 5b), which was indistinguishable from the WN/IC-P991 parental virus [6.4 vs 7.2 $\log_{10}$ p.f.u. (ml serum)$^{-1}$; $P>0.5$].

The cumulative attenuating effect of the prM-I141T and E-S156P substitutions on viraemia was also assessed in HOFIs. Similar to the results observed in HOSPs, HOFIs inoculated with the WN/IC-prM.E mutant developed a mean peak viraemia that was 38 000-fold lower than the parental WN/IC-P991 virus ($P<0.001$) and was indistinguishable from the WN-MX03/IC virus ($P>0.1$) (Fig. 6). Restoration of the high-viraemia phenotype was observed in HOFIs inoculated with the mutant virus in which the prM-141I and E-156S substitutions had been incorporated into the TM171-03-pp1 clone backbone (WN-MX03/IC-prM.E). Peak viraemias in HOFIs inoculated with this mutant reached 7.4 $\log_{10}$ p.f.u. (ml serum)$^{-1}$ and were indistinguishable from the WN/IC-P991 virus ($P>0.5$).

**Sequence analyses**

All desired nucleotide/amino acid changes were present and no additional non-synonymous amino acid substitutions or non-coding nucleotide changes were introduced while generating the 14 chimeric WN/IC NY99/MX03 viruses.
(Table 1). Amplicons generated from peak viraemia serum sample time points of a select number of AMCRs inoculated with the WN/prM.E virus were sequenced and compared with the consensus sequence from the viral inoculum. An amplicon of ~2 kb consisting of a portion of the WNV prM and E genes (genomic positions 301–2206) was sequenced. Sequencing of amplicons from all AMCR sera failed to identify any mutations at the prM-141 and/or E-156 amino acid positions or alternative compensatory mutations within this gene region. Additionally, sequence analyses performed on viral RNA extracted from the brains of AMCRs that succumbed to infection demonstrated no reversions or compensatory amino acid changes in these same gene regions.

### DISCUSSION

The epidemiological and/or biological basis for the paucity of WNV isolations from Central/South America, Mexico and the Caribbean has not been explored fully. The recent incursion into North America by WNV has coincided with a reduction in St Louis encephalitis virus (SLEV) activity in certain enzootic habitats within the USA, suggesting that WNV could potentially displace enzootic transmission by flaviviruses imparting heterologous immunity in similar maintenance hosts (Gibbs et al., 2006; Reisen et al., 2008). These epidemiological findings have been supported by experimental studies that indicate a higher replicative fitness of WNV in avian studies compared with SLEV genotypes (Reisen et al., 2005), as well as a reduced susceptibility to infection of previously flavivirus-infected mosquitoes (Pesko & Mores, 2009). Serological cross-protection between these flaviviruses in HOFIs has been demonstrated to result in a diminished avian viraemia following heterologous flavivirus challenge, providing further evidence to support cross-neutralizing flavivirus immunity as a potential factor dampening the force of transmission in more tropical latitudes where transmission of a more expansive group of flaviviruses has been described (Fang & Reisen, 2006). Competition with other closely related flaviviruses such as Bussuquara, Ilheus and Rocio viruses and SLEV for naïve vertebrate hosts could reduce the force of transmission by dampening avian viraemia and diminishing WNV-associated avian mortality observed in Latin America and the Caribbean (Gubler, 2007). Monitoring WNV consensus genotypes within emerging transmission foci for genetic changes influenced
by selective constraints imposed by transmission within new ecosystems will be critical for assessing viral phenotypic modulation in response to adaptation to new ecological niches.

Since the first documentation of WNV incursion into Latin America in 2003, a scarcity of isolates has been reported, despite widespread serological evidence of viral transmission (Johnson et al., 2010). Most isolates have been found in Mexico in close proximity to the US border and in Puerto Rico (Barrera et al., 2011; Deardorff et al., 2006); interestingly, these viruses have been representative of the North American genotype and have shared high degrees of genetic identity with viruses circulating in the USA. In contrast, the first WNV isolate (TM171-03) collected beyond the USA/Mexican border was isolated from a raven in Tabasco State in 2003. Phylogenetic analysis indicated this virus to be a member of the East Coast genotype, and introduction of this virus probably occurred via bird migration from the south-eastern USA directly or by way of the Caribbean (Deardorff et al., 2006). Reduced neuroinvasiveness in mice (Beasley et al., 2004) has been genetically correlated with the deletion of a single glycosylation motif within the E protein (E-S156P) that limited peripheral virus replication and dissemination into secondary tissues including the brain. The consensus sequence of the TM171-03-pp1 isolate identified prM-I141T, E-S156P, NS4B-I245V and NS5-T898I amino acid substitutions and three 5’UTR and five 3’UTR nucleotide changes compared with the WNV NY99 isolate (Beasley et al., 2004). A glycosylated large-plaque-forming variant (TM171-03-ppp5) and a non-glycosylated E protein small-plaque mutant (TM171-03-pp1) of the WNV TM171-03 isolate demonstrated different degrees of attenuation in AMCRs and HOSPs when compared with NY99 (Braught et al., 2011), with the non-glycosylated plaque variant displaying greater attenuation in both avian species than the glycosylated virus. However, in addition to having a functional glycosylation motif, the large-plaque variant (TM171-03-ppp5) also contained a NS5-R224G amino acid substitution and one 5’UTR and one 3’UTR nucleotide difference (mixed in TM171-03-pp1) compared with the small-plaque variant (TM171-03-pp1) (Beasley et al., 2004), thus requiring the use a reverse genetics approach to conclusively implicate the genetic determinant(s) associated with altered avian fitness of these plaque variants. This approach also allowed the introduction of various amino acid substitution combinations to identify synergistic and/or compounding effects of multiple amino acids on the viral phenotype in birds. Incorporation of the prM-I141T or E-S156P mutations individually resulted in viruses exhibiting varying degrees of growth attenuation that was avian species specific. A virus mutant containing the E-S156P substitution, eliminating the N-linked glycosylation motif, exhibited significantly altered peripheral growth in the highly susceptible AMCRs but had only a modest effect in HOSPs. Incorporation of the prM-I141T substitution into the WNV NY99 backbone alone significantly lowered viraemia in HOSPs but alone had no discernible effect in AMCRs. Introduction of both prM-I141T and E-S156P substitutions into the NY99 genetic backbone was required to fully attenuate the virus to the level of the TM171-03-pp1 plaque variant in AMCRs and HOSPs. Single mutants were not assessed in HOFIs; however, inoculation of HOFIs with the double mutant demonstrated a viraemia profile indistinguishable from that of the TM171-03-pp1 plaque variant. Interestingly, restoration of virulence levels indistinguishable from the parental NY99 strain was identified when both HOSPs and HOFIs were inoculated with the mutant virus containing both prM-141I and E-156S substitutions in the TM171-03-pp1 genetic backbone.

Together, these structurally non-conserved amino acid changes could impact host immune recognition and/or receptor-binding efficiency, as the prM and E proteins interact closely with each other to shape the outer-virion surface composition. On the surface of immature or partially mature WNV virions, the prM and E proteins interact to form stable trimers in which the prM restricts premature rearrangement of the E protein and subsequent fusion in low-pH secretory vesicles prior to exocytosis from the cell (Stiasny & Heinz, 2006). The fusion loop on domain II of the WNV E protein is protected until ~90 aa of the prM are cleaved by a cellular furin protease during exportation through the secretory pathway in the host Golgi. The subsequent cleavage of prM to M protein results in a structural rearrangement of the envelope homodimers for presentation of the receptor-binding motifs in domain III, resulting in the formation of a mature infectious virion (Heinz & Allison, 2000). The prM-I141T mutation is predicted to lie within a transmembrane domain involved in anchoring the prM protein to the lipid membrane of the host-cell endoplasmic reticulum (Li et al., 2008). WNV prM amino acid alignments demonstrate this transmembrane domain to be highly conserved, and the isoleucine at position 141 has been found in all other WNV isolates analysed (Misra & Schein, 2007). Analysis of dengue virus prM–E crystal structures has revealed that large conformational changes probably occur in the prM protein transmembrane regions during low-pH-induced virion maturation to infectious viral particles (Zhang et al., 2003). The less hydrophobic prM-I141T amino acid substitution could potentially hinder the low-pH conformational modifications of the prM protein that expose the viral furin cleavage site to cellular furin. This could directly impact on the proportion of immature envelope protein trimers versus mature dimers presented on the virion surface.

Previous studies have demonstrated that virus maturation impacts host neutralizing antibody recognition of viral epitopes, and the percentage of mature dimers on the virion surface is a major determinant of viral receptor-mediated infectivity (Heinz et al., 1994; Nelson et al., 2008). Decreased furin cleavage efficiency of the prM and E protein instability, due to a lack of N-linked glycans, could contribute to the attenuated phenotype observed in this study. Incorporation of the prM and E mutations individually demonstrated...
some level of reduced viral growth within the avian *in vitro* and *in vivo* systems reported here; however, it is unclear whether the attenuation effects of these mutations are cumulative or synergistic. The presence of mutations identified in these studies that restrict viral growth in avian hosts could be the result of immune selective pressures imposed by pre-existing flaviviral immunity in avian hosts. Future studies are warranted to assess the relative fitness of mutant viruses expressing these genetic changes compared with parental NY99 and TM171-03-ppl viruses in the presence of avian immunoglobulin generated to heterologous flaviviral infections. Alternatively, the presence of highly attenuating mutations in circulating WNV strains in Mexico could have resulted from genetic drift in which the introduction of a limited viral genetic population into Latin America, perhaps by a migratory bird, as has been suggested previously (Deardorff *et al.*, 2006), could have randomly initiated transmission with a low-fitness variant. Once available, analyses of more WNV sequences from transmission foci in Mexico, Central America, the Caribbean and South America will allow further assessment of this founder-effect theory. Regardless of the evolutionary forces that have resulted in a genotype of WNV isolated from Mexico with reduced avian viraemia potential, it is apparent that, despite the reduced growth capacity in avian hosts reported here, these viruses maintain the potential to be transmitted by certain highly susceptible avian hosts. Viruses that contained both prM and E mutations generated peripheral titres as high as 5 log₁₀ p.f.u. (ml serum)⁻¹ in AMCRs and HOFIs, a level likely to be permissive for infection of competent *Culex* spp. mosquito vectors (Dohm & Turell, 2001; Dohm *et al.*, 2002). The significantly diminished peripheral viraemias in birds would undoubtedly reduce the efficiency of infection of enzootic mosquito vectors and diminish the force of transmission where these genotypes circulate. Such a reduction in the force of transmission is consistent with the low incidence of human and equine disease reported in parts of Latin America. Furthermore, the reduced viral growth due to the presence of these mutations could also explain the lack of avian mortality observed south of the USA–Mexico border. Additional studies utilizing sympatric avian hosts with locally isolated WNV isolates will be needed to address this hypothesis further.

**METHODS**

*Plasmids and infectious cDNA clones.* All WNV TM171-03-ppl/ NY99 point mutants and chimeras were generated using a two-plasmid infectious clone system (pWN-AB and pWN-CG) described previously (Kinney *et al.*, 2006). Site-directed mutagenesis was carried out on pWN-AB cDNA to introduce single or combinations of TM171-03-ppl structural amino acid (prM-I141T and E-S156P) and 5’UTR mutations. Similarly, mutagenesis was performed for incorporation of individual or combinations of mutations of the N54B-I245V, N55-T898I and 3’UTR mutations, with pWN-CG. Different pairings of mutated and wild-type pWN-AB and pWN-CG cDNAs were ligated in *vitro*, as described previously (Kinney *et al.*, 2006), to generate the various mutations. Transcription of the resulting full-length cDNAs was performed using a T7 RNA AmpliScribe kit with 6 mM m⁷G (5')ppp(5')A cap analogue based on the manufacturer’s instructions (Epicentre). *In vitro*-transcribed RNA was transfected into baby hamster kidney cells using a Petri pulser (BTX), propagated once in Vero cells and quantified by plaque assay in Vero cells for use in *all in vitro* and *in vivo* experiments. Viral RNA was extracted from the viral stocks, and the complete genomes of all rescued viruses were sequenced as described previously (Kinney *et al.*, 2006) to verify maintenance of the desired mutations in all rescued viruses.

*In vitro growth profiles.* Select WN/IC mutants were inoculated onto Vero and avian macrophage HD11 cells at an m.o.i. of 0.01 in triplicate using six-well plates. Briefly, the viral inoculum was allowed to adsorb for 1 h at 37 or 41 °C for Vero and HD11 cells, respectively. Monolayers were washed twice with PBS, and 4.5 ml Dulbecco’s minimal essential medium (DMEM; Vero cells) and RPMI 1640 (HD11 cells) supplemented with 5% FBS and 100 U penicillin/ streptomycin ml⁻¹ was added to each well. One hundred microlitres of supernatant was collected at 12, 24, 48 and 72 h p.i. for HD11 cells and every 24 h p.i. for 5 days for Vero cultures. Sampled supernatants were diluted 1:10 using the same culture medium containing 20% FBS and stored at −80 °C until titration by standard plaque assay in Vero cells, as described previously (Braught *et al.*, 2004). This dilution and the plating of a 200 µl inoculum for plaque assays resulted in a detection limit of 50 p.f.u. (ml supernatant)⁻¹.

*Avian infection and sero-sampling.* Wild-caught AMCRs, HOSPs and HOFIs were held for at least 2 weeks for acclimation to cage conditions prior to inoculation with recombinant viruses. AMCRs were captured by cannon net in Bellvue, CO, USA, whilst HOSPs and HOFIs were collected using grain-baited ground traps and mist nets in Bakersfield, CA, USA. Samples of 0.2 and 0.1 ml blood were drawn by jugular venipuncture from AMCRs and HOSPs/HOFIs, respectively, and serum collected in serum separator tubes was tested for the presence of neutralizing antibodies to WNV and SLEV by a 90% plaque reduction neutralization test, as described previously (Braught *et al.*, 2004). Groups of eight AMCRs and six HOSPs or HOFIs were inoculated subcutaneously in the breast region with 1500 p.f.u. of each virus using a 27-gauge needle. Blood was collected from birds daily by jugular venipuncture up to 7 days p.i. Whole blood was added to diluent (DMEM with 20% FBS) at a dilution of 1:10, allowed to coagulate at room temperature for 30 min and centrifuged at 2500 g for 10 min. The sera were stored at −80 °C until titrated for infectious units in Vero cells by plaque assay.

*Avian viral load quantification and plaque size evaluation.* Daily blood samples were assayed by plaque formation on monolayers of Vero cells. In addition, avian inocula for all viruses were back titrated by plaque assay to confirm the uniformity of the doses administered. Briefly, serial tenfold dilutions of serum were inoculated onto Vero cells that were overlaid as described previously (Braught *et al.*, 2004). Plaques were enumerated at 72 h p.i. and multiplied by the dilution factor to determine viral titres (ml serum)⁻¹. An initial 1:10 dilution of serum, as well as the use of 200 µl of the lowest dilution, resulted in a limit of detection of 1.7 log₁₀ p.f.u. ml⁻¹. Plaque size determination was performed at 72 h p.i. by measuring the diameter of ten well-delineated viral plaques.

*Sequencing.* All full-length consensus sequences were generated using primer sets described previously (Lanciotti *et al.*, 1999). Briefly, total viral RNA from 140 µl culture supernatant was extracted using a QIAamp Viral RNA Mini kit according to the manufacturer’s instructions (*Qiagen*) and eluted in 80 µl nuclease-free water. Amplicons (∼2.5 kb each) were generated using a one-step RT-PCR kit (Invitrogen), purified by gel extraction (*Qiagen*) and used for direct sequencing on an ABI 3130x Genetic Analyser. WNV RNA was
extracted from AMCR serum samples (4 or 5 days p.i.) and brain tissue at time of death/euthanasia. RT-PCR was used to generate amplicons using primers that flanked the prM-141 and E-156 loci (Ke301: 5’-TGGAGAGGTGTGAAACAACAAAC-3’, WNc2206: 5’-CCTTGAGGTTGTGTAAAGG-3’) and sequenced to confirm the genetic identity at these positions following growth in AMCRs. All prM–E amplicons (~2 kb) generated from AMCR samples were compared with the original bird inoculum consensus sequence to assess genetic identity.

**Statistical analyses.** Statistical analyses were performed on the duration of viraemia and peak viraemia for all experimental bird samples by analyses of variance. Multiple comparisons (i.e. confidence intervals for the difference of means) were performed using Tukey’s HSD adjustment for comparisons of means. A level of significance of P<0.05 was used for all comparisons.

**ACKNOWLEDGEMENTS**

Vincent Martinez and Brian Carroll provided invaluable avian collection and animal husbandry support for this project. Funding for these studies was provided by grants from the National Institutes of Health (AI016822 and AI55606) and the Centers for Disease Control and Prevention grant (C1000235). Trapping of AMCRs and HOIs was performed under US Fish and Wildlife Scientific Collecting Permit MB-032526 and MB-082812 and Resident Scientific Collection Permit 801049-02 by the State of California Department of Fish and Game. Collection, husbandry and experimental inoculations of birds were performed under approved UC Davis IACUC protocols.

**REFERENCES**


